Management of chronic pain and opioid dependence with buprenorphine/naloxone

The prevalence of chronic pain is estimated to be 20% to 40% worldwide, in which the rates of opioid addition ranged between 8% and 12% 1 . The consequences of opioid misuse cause significant morbidity and mortality and the treatment of chronic pain with opioid addiction is challenging. Here we present a patient with chronic pain and opioid use disorder who was treated successfully with buprenorphine/naloxone (Suboxone®). The patient signed informed consent and anonymity has been preserved. The study is approved by the Ethics Committee of the Taipei City Hospital and conformed to the provisions of the Declaration of Helsinki.